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Background
TB remains a major killer amongst infectious diseases and
current treatment involves a four-drug regimen for at least
six months. Clinical development of a single novel TB
drug is expected to take at least six years. A completely
novel combination regimen would require twenty years or
more. New drugs and regimens are required to shorten
treatment duration, reduce toxicity and combat drug
resistance.
We reviewed the ability of short-term outcomes from
phase II trials to predict longer-term outcomes from
phase III trials and hence improve selection of optimum
combinations of new and existing drugs for development
in pivotal trials.
Methods
Phase II or phase III trials of combinations of eight
agents for drug sensitive individuals with tuberculosis
were included in our systematic review. Definitive clinical
endpoints included treatment failure and treatment
relapse. Early clinical endpoints incorporated positive or
negative culture at various time points, time to sputum
culture conversion and serial viable colony counts.
For categorical data, the odds ratio will be calculated
using the Mantel-Haenszel method, and for continuous
data, such as colony counts, the mean difference will be
calculated. Time to event outcomes will be summarised
via the generic inverse-variance method. Additionally,
early endpoints will be evaluated as surrogate outcomes
for poor outcome via the generalised R2 statistic.
Results
2865 trials were identified for potential inclusion in the
review. Of these, 47 phase II and 478 phase III trials were
included. Data is currently being extracted and full results
will be presented.
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